spironolactone has been researched along with Compensatory Hyperinsulinemia in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of mineralocorticoid receptor blockade by spironolactone have been shown in animal models of non-alcoholic fatty liver disease (NAFLD)." | 9.24 | Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. ( Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA, 2017) |
| "The aim of our study was to compare serum leptin levels in patients with primary hyperaldosteronism (PA) with those of healthy subjects and to explore the relationship of serum leptin levels and the parameters of insulin action in these patients before and after surgical or pharmacological treatment." | 7.71 | Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. ( Haluzík, M; Prázný, M; Sindelka, G; Skrha, J; Widimský, J; Zelinka, T, 2002) |
| "The beneficial effects of mineralocorticoid receptor blockade by spironolactone have been shown in animal models of non-alcoholic fatty liver disease (NAFLD)." | 5.24 | Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. ( Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA, 2017) |
| "The aim of our study was to compare serum leptin levels in patients with primary hyperaldosteronism (PA) with those of healthy subjects and to explore the relationship of serum leptin levels and the parameters of insulin action in these patients before and after surgical or pharmacological treatment." | 3.71 | Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. ( Haluzík, M; Prázný, M; Sindelka, G; Skrha, J; Widimský, J; Zelinka, T, 2002) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Polyzos, SA | 1 |
| Kountouras, J | 1 |
| Mantzoros, CS | 1 |
| Polymerou, V | 1 |
| Katsinelos, P | 1 |
| Alexander, S | 1 |
| Anazodo, A | 1 |
| Hussain, K | 1 |
| Svendsen, PF | 1 |
| Nilas, L | 1 |
| Nørgaard, K | 1 |
| Madsbad, S | 1 |
| Haluzík, M | 1 |
| Sindelka, G | 1 |
| Widimský, J | 1 |
| Prázný, M | 1 |
| Zelinka, T | 1 |
| Skrha, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study[NCT01147523] | Phase 2 | 30 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
1 trial available for spironolactone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Combined Modality Th | 2017 |
2 other studies available for spironolactone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Interactions of diazoxide with frusemide, spironolactone, and acetylsalicylic acid in a patient with hyperinsulinism of Infancy and Fallot tetralogy.
Topics: Aspirin; Diazoxide; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Furosem | 2003 |
Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity.
Topics: Adrenal Glands; Adrenalectomy; Adult; Female; Glucose Clamp Technique; Humans; Hyperaldosteronism; H | 2002 |